key: cord-0957781-6sbf7a2z
authors: Freeman, Esther E.; Chamberlin, Grace C.; McMahon, Devon E.; Hruza, George J.; Wall, Dmitri; Meah, Nekma; Sinclair, Rodney; Balogh, Esther A.; Feldman, Steven R.; Lowes, Michelle A.; Marzano, Angelo V.; Naik, Haley B.; Castelo-Soccio, Leslie; Lara-Corrales, Irene; Cordoro, Kelly M.; Mahil, Satveer K.; Griffiths, Christopher E.M.; Smith, Catherine H.; Irvine, Alan D.; Spuls, Phyllis I.; Flohr, Carsten; French, Lars E.
title: Dermatology COVID-19 Registries: Updates and Future Directions
date: 2021-05-31
journal: Dermatol Clin
DOI: 10.1016/j.det.2021.05.013
sha: 052f14cbeedba90be6248d45c1788a1ff9202c44
doc_id: 957781
cord_uid: 6sbf7a2z

During the COVID-19 pandemic, rapid, real-world evidence is essential for the development of knowledge and subsequent public health response. In dermatology, provider- and patient-facing registries focused on COVID-19 have been important sources of research and new information aimed at guiding optimal patient care. The seven dermatology registries included in this update now include over 8,000 case reports sourced from physicians and patients from countries all over the world.

The world has now been dealing with the unprecedented effects of the COVID-19 pandemic for over a year with a global case count that has surpassed 135 million as of April 2021. 1 Accurate reporting of cases, symptoms, and treatment of the causative virus, SARS-CoV-2, has been critical to the development of knowledge and subsequent public health response. Registries have played an important role in collecting real-world evidence during the pandemic. Due to their rapid, harmonized, international response, the seven dermatology groups included in this update have been managing and analyzing registry data for almost as long as the pandemic has been spreading. Launched during March and April of 2020, these registries─ focused on the relationship between COVID-19 and dermatology─ have now cumulatively collected over 8,000 case reports sourced from all over the world (Table 1) . This paper will serve as an update 2 on their objectives, findings, and future goals in the ever-evolving COVID-19 landscape.

After initial reports from Italy and China of COVID-19 associated dermatologic manifestations, leaders from the American Academy of Dermatology (AAD) and the International League of Dermatological Societies (ILDS) founded a registry on April 9, 2020 in order to understand and better form hypotheses about this interplay between the skin and COVID-19. 3 Understanding that frontline healthcare workers needed reliable information, AAD and ILDS leadership worked rapidly to bring the registry from the idea generation phase to the collection of first patient data in just eight days. 4 In an effort to capture as much data as possible, entries are internationally crowdsourced from any physician or other health care provider seeing patients with COVID-19 and possible skin symptoms or patients who have pre-existing dermatologic conditions that might be potentially affected by COVID-19.

The AAD/ILDS COVID-19 Dermatology Registry now has 1,875 entries from 52 countries as of March 2021. Registry data have demonstrated the wide spectrum of dermatologic manifestations of COVID-19, ranging from pernio/chilblains in relatively mild COVID-19 to retiform purpura in ill, hospitalized patients. 5, 6 The most common dermatologic morphologies in 716 patients, in the subset of COVID-19 laboratory-confirmed cases, included morbilliform (22%), pernio-like (18%), urticarial (16%), macular erythema (13%), vesicular (11%), papulosquamous (9.9%), and retiform purpura (6.4%) morphologies. 5 Other registry publications have focused on the importance of the time of testing in relation to the onset of dermatologic symptoms: PCR test results earlier in the disease course were more likely to be positive, even when date of onset was defined by cutaneous manifestations rather than systemic symptoms. 7 The registry also demonstrated that skin symptoms are experienced by "long-haulers," those who experience COVID-19 symptoms for weeks or months after initial infection. 8 Pernio, or "COVID toes," in particular, may last for many months, raising the question about persistent inflammation in these patients. 9 In addition to these findings, data from the registry have been used to inform public health policy. In multiple states, COVID toes are part of their testing criteria and have served to highlight the importance of dermatologic data for characterizing the different phenotypes of COVID-19.

The majority (75%) of registry entries were of new-onset dermatologic manifestations in the setting of COVID-19. However, the registry still collected ~5% of total cases on outcomes of patients with dermatologic conditions on immunosuppressive medications and was able to collaborate with PsoProtect and SECURE-AD to share these cases. Additionally, there were multiple cases of post-COVID-19 telogen effluvium, which the AAD/ILDS registry has worked with SECURE-Alopecia to document.

Given the importance of data sharing and allowing other investigators to explore important COVID-19 dermatology questions, the AAD/ILDS registry has established a data J o u r n a l P r e -p r o o f request process whereby investigators can apply for access to registry data. 10 Additionally, the AAD/ILDS registry has added a new module on COVID-19 cutaneous vaccine reactions to characterize reactions to COVID-19 vaccines; 11 526 vaccine reactions have already been reported. The aim of this characterization is to understand the types of reactions that can present and to provide data that may prove reassuring to patients and healthcare providers regarding the ability to receive a second dose (in vaccines that require two doses) for patients with cutaneous reactions to the first dose.

Emerging evidence regarding the potential of multiple therapies utilized in patients with alopecia (including hydroxychloroquine, antiandrogens, and JAK inhibitors such as Baricitinib) to alter COVID-19 outcomes prompted a core team from Ireland, the UK, and Australia to launch

Alopecia. After engaging an internationally recognized network of hair experts to define a dataset harmonized with SECURE-Atopic Dermatitis (SECURE-AD, described below) the registry was launched on April 8, 2020 to record data of COVID-19 positive patients with scarring and non-scarring alopecia, both on and off treatment. [12] [13] [14] The primary objective was to uncover the underlying determinants of outcomes of COVID-19 positive patients with any form of alopecia and also to assess the impact of COVID-19 on alopecia ─ such as the development of telogen effluvium.

As of March 5, 2021, there were 229 cases from 14 countries in the SECURE-Alopecia registry. While initial data has been presented at a meeting of the American Hair Research Society and numerous educational meetings, a formal analysis has not yet been published as the diversity of the data has necessitated greater recruitment. The international steering committee has led to two publications regarding alopecia therapeutics during the COVID-19 era and the development of patient registries during a pandemic. 15, 16 J o u r n a l P r e -p r o o f

The pressure on health services to prioritize acute and emergency care during the pandemic has understandably reduced the capacity for clinicians to follow patients with alopecia. As the pandemic has progressed and services have become more accessible, the number of cases entered in SECURE-Alopecia has increased. The delayed emergence of telogen effluvium (TE) has also contributed to greater reporting of cases with time. TE is a nonscarring alopecia that results in diffuse alopecia. 17 Immediate anagen release─ when large numbers of anagen follicles are triggered to prematurely enter catagen and then telogen 18 ─ is classically associated with high fever and certain medications and the timing mirrors the mean time from SARS-CoV-2 diagnosis in a study of 195 patients who developed acute TE. 19 While pro-inflammatory cytokines or medication were proposed as potential triggers, it is interesting that 10% of patients experienced subclinical disease. 19 A more immediate, presumed dystrophic anagen effluvium has been reported in a single case report, though further evidence is required to validate this. 20, 21 It is expected that SECURE-Alopecia will contribute to a better understanding of this component of "long COVID". SECURE-Alopecia is based on a dataset developed by SECURE-IBD, an international database used to track cases of COVID-19 in patients with inflammatory bowel disease. SECURE-Alopecia is matched with SECURE-AD and is also closely aligned with PsoProtect, the AAD/ILDS registry, and other inflammatory disease registries in order to enable comparative analyses. SECURE-Alopecia is engaged in ongoing discussions with these and other registries to ensure collaboration as data collection progresses. Collaboration with other registries is also of considerable interest to the steering committee, particularly with respect to cases where immunomodulatory therapies have been utilized.

In view of the delayed reporting of cases of alopecia and the emerging cases of telogen and anagen effluvium that are being described, SECURE-Alopecia intends to continue to recruit J o u r n a l P r e -p r o o f cases for the foreseeable future and will also aim to extend its dataset to analyze the impact of vaccination on alopecia.

The SECURE-Atopic Dermatitis (SECURE-AD) registry went live on April 1, 2020 as an international collaboration of dermatologists, epidemiologists, and patient experts. The primary objective is to uncover the underlying determinants of outcomes of COVID-19 in patients with SECURE-AD has been collaborating with the SECURE-IBD, PsoProtect, SECURE-Alopecia, and AAD/ILDS registries and comparative analyses between these different data sets are planned for the future. SECURE-AD intends to continue to recruit cases for the foreseeable future and will also aim to extend its dataset to analyze the impact of vaccination on AD. 93% of reported patients fully recovered from COVID-19, 21% were hospitalized, and 9 patients (2%) died. There were no significant differences found between classes of biologics, but biologic use was associated with a lower risk of COVID-19-related hospitalization compared with nonbiologic systemic therapies. The PsoProtect authors highlight the need for further investigation J o u r n a l P r e -p r o o f into this on account of potential selection biases (e.g. most patients reported to PsoProtect were receiving biologics) and unmeasured confounding (e.g. potential differences in risk mitigating behaviors between treatment groups).

An analysis of self-reported data from 2,869 people with psoriasis reporting to PsoProtectMe was subsequently published in the British Journal of Dermatology. 23 The SECURE-Psoriasis registry has recorded over 30 reported cases in recent months, both from the United States and internationally. The registry has shared its data with a number of other COVID-19 registries for patients with dermatologic conditions, including PsoProtect, resulting in multiple internationally collaborative manuscripts such as the review of 374 psoriasis patients with confirmed COVID-19 described above. 22 Another shared publication discusses the importance of collaborative development of interoperable patient registries. 16 The data gathered through SECURE-Psoriasis and other registries for psoriasis patients 

In healthcare provider-reported cases, COVID-19 severity ranged from asymptomatic to moderate (11.1% asymptomatic, 77.8% mild, 11.1% moderate). No difference in virus severity was observed between patients taking biologics and not taking biologics (p=0.3). Shortness of breath and acute respiratory distress syndrome were infrequently reported (4 of 27 cases, 13.3%). There was no difference in COVID-19 severity between those who continued and those who discontinued biologics (p=0. 3) . No instances of death, strokes, myocardial infarctions, heart failure, or sepsis were reported by patients or providers.

These initial findings have guided use of biologic therapies in patients with HS, and informed knowledge of the safety of TNF, IL-1, IL-17 and IL-12/23 inhibitors in the overall setting of COVID-19. By confirming the continued use of disease-altering therapies throughout the pandemic, these findings have potentially aided in reducing urgent care and emergency room healthcare utilization by HS patients with disease flares. Overall, initial findings from patient-and provider-reported cases indicate that COVID-19 severity in HS patients was mild to moderate, with no difference in COVID-19 severity between those taking and not taking biologics, nor between those who continued vs. discontinued biologic treatment.

The team plans to examine HS outcomes in comparison with other inflammatory skin disease outcomes. As an extension of this work, HS COVID is considering collecting data on the vaccination preferences and experiences of people living with HS. These data will inform HS management for this and future pandemics and public health crises.

With a goal of creating a pediatric-specific international registry for acral skin changes, There are certainly limitations to the conclusions that can be drawn from registry data.

For example, an important limitation of these registries is their lack of information on the total population at risk for any event of interest, be it dermatological manifestations of COVID-19 or J o u r n a l P r e -p r o o f outcomes such as death or hospitalization. Thus, the data cannot be used to calculate the incidence or prevalence of any complications of COVID-19 in the population at large. Geographically, 87% and 56% of SECURE-Psoriasis and HS COVID cases (respectively) are from North America, and 70% of PEDRA cases are from the United States. This homogeneity has implications for the ability of registries to contribute generalizable scientific knowledge, especially for a pandemic that has touched all continents and disproportionately afflicted communities of color. In the end, conclusions drawn from these registries are only as good as the data entered. There is still work to be done in ensuring equitable representation of the global dermatologic patient community.

That said, registry data has been instrumental in enhancing scientific knowledge during the pandemic. By providing a platform where physicians and, in some cases, patients can enter their observations, a registry can crowd-source disparate findings from around the world, facilitating the recognition of recurrent patterns. Registry data led to the understanding of the "spectrum" of cutaneous manifestations of the virus: pernio-like lesions are associated with mild COVID-19 while retiform purpura is only seen in severe COVID-19 patients requiring intensive care. 5 Other hypotheses generated from this real-world evidence have influenced the advancement of scientific knowledge about the virus, its various manifestations, and patient J o u r n a l P r e -p r o o f care, as in the cases of recognizing "COVID toes" as a symptom of the virus or providing reassuring data on use of biologics and immunosuppressive medications during the pandemic. 22 Furthermore, the synthesized data generated by these registries has been made widely accessible to professionals and the public through peer-reviewed publications and informative online platforms, 31,32 thus providing important guidance concerning COVID-19 disease symptoms in the general population and in patients with chronic skin diseases.

The immense amount of collaboration (Figure 1 ) between registries─ both within dermatology and with external registries documenting non-dermatological conditions─ was instrumental to this production of knowledge and should set a precedent for the harmonization of data collection in the international dermatology community moving forward. When the need for evidence-based answers is high and the availability of time and resources is low, collaboration can enhance the ability of researchers and medical professionals to provide quality information and care. Due to democratized access and less stringent inclusion criteria (as compared to clinical trials and studies), registries can better reflect 'real-world' evidence, especially when it comes to rare diseases or long-term complications and outcomes. 2, 16 All of the registries included in this paper intend to remain open for further case reporting. As the global vaccine rollout continues, at least five registries ─ AAD/ILDS, SECURE-Alopecia, SECURE-AD, PsoProtect, and HS COVID ─ are collating information on patients' COVID-19 vaccine complications and experiences into their work. The biggest and most critical shared goal is the continued collaboration between registries as they work towards their shared objectives ( Table 2) 

WHO Coronavirus (COVID-19) Dashboard. Accessed

International collaboration and rapid harmonization across dermatologic COVID-19 registries

The American Academy of Dermatology COVID-19 registry: Crowdsourcing dermatology in the age of COVID-19

AAD Registry for Skin Manifestations of COVID-19: Q&A With Dr Freeman. The Dermatologist

The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries

Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries

Timing of PCR and Antibody Testing in Patients with COVID-19 associated dermatologic manifestations

Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. The Lancet Infectious Diseases

Cold and COVID: Recurrent Pernio during the COVID-19

COVID-19 Dermatology Registry Data Request Application

Cutaneous Reactions Reported after Moderna and Pfizer COVID-19 Vaccination: A Registry-Based Study of 414 Cases

The Alopecia Areata Consensus of Experts (ACE) Study: Results of an International Expert Opinion on Treatments for Alopecia Areata

The Alopecia Areata Consensus of Experts (ACE) Study PART II: Results of an International Expert Opinion on Diagnosis and Laboratory Evaluation for Alopecia Areata

A Global eDelphi Exercise to Identify Core Domains and Domain Items for the Development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS)

Shedding light on therapeutics in alopecia and their relevance to COVID-19

Learning from disease registries during a pandemic: moving towards an international federation of patient registries

Telogen Effluvium: New Concepts and Review

SARS-CoV-2-induced telogen effluvium: a multicentric study

What can the hair tell us about COVID-19?

COVID-19 related anagen effluvium

Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study

Risk mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

International Federation of Psoriasis Associations